Excelsior Advisor Network LLC Acquires New Holdings in United Therapeutics Corporation $UTHR

Excelsior Advisor Network LLC acquired a new position in United Therapeutics Corporation (NASDAQ:UTHR) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 979 shares of the biotechnology company’s stock, valued at approximately $581,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Torren Management LLC bought a new position in shares of United Therapeutics in the fourth quarter valued at approximately $26,000. Activest Wealth Management raised its holdings in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares in the last quarter. WealthCollab LLC lifted its position in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. lifted its position in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new position in United Therapeutics during the 4th quarter valued at $31,000. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on UTHR shares. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. JPMorgan Chase & Co. lifted their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a research report on Thursday, May 7th. Finally, Raymond James Financial assumed coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $648.33.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $578.58, for a total transaction of $5,785,800.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,921,276.08. The trade was a 34.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders have sold 493,833 shares of company stock worth $275,841,047. Insiders own 8.60% of the company’s stock.

United Therapeutics Trading Down 0.1%

Shares of UTHR opened at $527.94 on Tuesday. The business’s 50-day moving average price is $547.10 and its 200 day moving average price is $531.86. The stock has a market capitalization of $22.41 billion, a P/E ratio of 19.49, a P/E/G ratio of 1.77 and a beta of 0.58. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the company posted $6.63 earnings per share. On average, research analysts predict that United Therapeutics Corporation will post 26.65 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.